Monitor for initial prescription data and revenue contribution from Japan in upcoming quarters. The pediatric expansion (ages 4-11) is a first globally and could drive incremental volume. Watch for regulatory decisions in other countries reviewing pediatric label expansion.
Price Chart
Executive Summary
Pharming announced the commercial launch of Joenja (leniolisib) in Japan for APDS patients aged 4+, following NHI drug price list inclusion. Japan is the first market where Joenja is available for children aged 4-11. This expands Pharming's global footprint into a new geography with a partner handling distribution, but no revenue or financial guidance was provided.
Key Facts
- Joenja (leniolisib) commercially launched in Japan for APDS patients aged 4+
- Japan is the first market where Joenja is available for children aged 4-11
- Launch follows MHLW approval in March 2026 and NHI drug price list inclusion
- OrphanPacific, Inc. is the Marketing Authorization Holder responsible for supply and distribution
- Joenja is already approved in the U.S., U.K., EU, Australia, Israel, Canada, South Korea, and Saudi Arabia for patients 12+
- Leniolisib is under regulatory review for pediatric patients in several other countries
Financial Impact
No financial terms disclosed; revenue impact from Japan launch is unquantified but represents a new commercial market for Joenja
Risk Factors
- No revenue or pricing details disclosed for Japan launch
- Japan is a small market for ultra-rare diseases (~1-2 per million prevalence for APDS)
- Dependence on OrphanPacific for distribution and supply chain execution
- Forward-looking statements with no hard financial guidance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001828316-26-000035 |
| Document: 0001828316-26-000035-index-headers.html | 0001828316-26-000035 |
| Document: 0001828316-26-000035-index.html | 0001828316-26-000035 |
| Document: 0001828316-26-000035.txt | 0001828316-26-000035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 6-K | $11.21 $10.55 | ▼ −5.89% | ▼ −5.67% | $9.75 (−13.02%) |
Aug 13, 2026 7w ago | 6-K | $12.35 $11.68 | ▼ −5.43% | ▼ −3.46% | $9.75 (−21.05%) |
Jun 4, 2026 17w ago | 6-K | $12.47 $12.88 | ▲ +3.29% | ▲ +5.84% | $9.75 (−21.81%) |
May 28, 2026 18w ago | 6-K | $13.66 $12.24 | ▼ −10.40% | ▼ −10.35% | $9.75 (−28.62%) |
May 22, 2026 18w ago | 6-K | $13.62 $12.28 | ▼ −9.84% | ▼ −11.05% | $9.75 (−28.41%) |
Apr 16, 2026 24w ago | 6-K | $17.33 $16.64 | ▼ −3.98% | ▼ −4.97% | $9.75 (−43.74%) |
Mar 27, 2026 27w ago | 6-K | $16.31 $16.50 | ▲ +1.16% | ▼ −2.70% | $9.75 (−40.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access